GlassScriptPhysician profile
Joann O Ford
NPI 1689140170
$5,962.69
in general payments reported to CMS, 2019-2025
17 companies · $1,321 in 2025
The $1,321 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $777 · 2022: $262 · 2023: $1,819 · 2024: $1,783 · 2025: $1,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,824 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,823.73 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,628.34 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $931.87 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $707.89 | 2021-2025 | |
| Alkermes, INC. | $625.46 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $519.01 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $448.79 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $382.03 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Indivior INC. | $261.54 | 2023-2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $228.26 | 2021-2025 | Caplyta |
| Janssen Scientific Affairs, LLC | $53.36 | 2023 | Invega Sustenna |
| Noven Therapeutics, LLC | $44.34 | 2023-2024 | Xelstrym, Secuado |
| Bioxcel Therapeutics, INC. | $35.11 | 2023 | Igalmi |
| Vanda Pharmaceuticals INC. | $32.54 | 2023 | Fanapt, Hetlioz |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.02 | 2024 | Abilify Maintena |
| Lundbeck LLC | $17.78 | 2024 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.78 | 2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joann Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.